AC Immune Targeting $50m IPO
Alzheimer's disease drug and vaccine developer AC Immune SA is aiming to raise $50m via an initial public offering that will take the company public on Nasdaq in the US. This follows a successful series E financing round in May this year that saw the company net $43.5m.
You may also be interested in...
Novan and AC Immune ended September with the first biopharma IPOs in 40 days as the performance of newly public companies’ stocks head into an upswing.
The two drug developers that managed to launch initial public offerings in the US during the past two weeks had to accept rough haircuts in order to get investors to buy their newly issued stock.
The Scrip 100 universe gathers FY 2019 financial performance data and compares the activities of the Top 100 biopharma businesses, ranked by pharma sales. Here In Vivo breaks out the Top 10 in the league table. Which big pharma holds the top spot this year?